- Inflammatory bowel diseases, encompassing Crohn’s disease and ulcerative colitis, are chronic gastrointestinal disorders that require long-term management, making them a significant focus within the global healthcare landscape due to their growing prevalence and burden on patient quality of life
- The rising demand for effective IBD treatment is primarily driven by increasing incidence rates worldwide, greater awareness of gastrointestinal health, and the expanding utilization of biologics and small molecule therapies offering targeted and sustained remission
- North America dominated the inflammatory bowel diseases market with the largest revenue share of over 40.5% in 2024, attributed to advanced healthcare infrastructure, high diagnosis rates, significant R&D investments, and a strong pipeline of novel IBD treatments from leading pharmaceutical players in the U.S.
- Asia-Pacific is projected to be the fastest growing region in the IBD market during the forecast period, driven by increasing patient population, improving healthcare access, and heightened awareness and diagnosis of IBD across developing economies
- Ulcerative colitis segment dominated the inflammatory bowel diseases market with a market share of 53.5% in 2024, driven by its higher global prevalence, earlier diagnosis rates, and availability of a wide range of effective treatment options
